Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Thyroid Cancer, Papillary 1Sarcoma, Endometrial Stromal 1Neoplasm Metastasis 1Liver Neoplasms 1Leukemia, Hairy Cell 1Duodenal Neoplasms 1Carcinoma, Lobular 1Carcinoma, Hepatocellular 1Anatomic Stage I Breast Cancer AJCC v8 1Agnosia 1Adrenocortical Adenoma 1Adenocarcinoma, Follicular 1

Interventions

trebananib 1selurampanel 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1Imatinib Mesylate 1Ifosfamide 1High-Energy Shock Waves 1Fulvestrant 1Doxorubicin 1Chromatography, High Pressure Liquid 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Endometrial Stromal × High-Energy Shock Waves × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡